Introduction

Lung cancer is the leading cause of cancer related deaths in men and women (1) and is responsible for 1.6 million deaths per year worldwide (2). Non-small cell lung cancer (NSCLC) accounts for ~85% of lung cancers. Over the past decade, there has been a lot of emphasis on understanding driver mutations in NSCLC. Molecular testing for these mutations has advanced our understanding of NSCLC and resulted in genotype directed targeted therapy. Driver
mutations with approved targeted therapies include epidermal growth factor (EGFR) mutation, anaplastic lymphoma kinase (ALK) translocation, rat osteosarcoma (ROS1) translocation and BRAF mutation. Other mutations being actively investigated include human epidermal growth factor receptor 2 (HER2) mutation, mesenchymal epithelial transition (MET) abnormalities, rearranged during transfection (RET) translocation, RAS mutation and PIK3CA, AKT1 & phosphatase and tensin homolog (PTEN) alterations.

Proximal or central airway obstruction (CAO) complicates 20–30% of lung cancer cases (3) and is responsible for 40% of deaths (4). CAO can occur from varying mechanisms including direct luminal compromise, airway edema/inflammation, and destruction of airway cartilage. There are multiple bronchoscopic ablative techniques available for management of CAO. Common modalities include rigid bronchoscopy with mechanical debulking, laser, thermo-coagulation [electrocautery & argon plasma coagulation (APC)], cryotherapy, endobronchial brachytherapy (EBT), photodynamic therapy (PDT), intratumoral chemotherapy (ITC) and transbronchial needle injection (TBI) of chemotherapy. Selection of the appropriate modality depends on several factors including features of the tumor, the patient’s clinical presentation, and operator preferences.

Intuitively, the patients who would most often benefit from genotype directed therapy i.e., those with advanced NSCLC, would also be the ones who are most likely to need bronchoscopic ablative therapy. It would be important to understand the influence of driver mutations on outcomes of these procedures. For example, we need to know if certain mutations result in tumors which have higher complication rates with a given procedure. This would influence procedure selection and even the selection of a multi-modality approach. More importantly, we would also like to know if certain bronchoscopic procedure complement certain therapies. For example, will certain driver mutations have a better outcome if we were to combine the gene directed therapy for it with one procedure as opposed to another. Unfortunately, there is very little literature in this field. The scope of this review is to consolidate our current knowledge of immunologic markers of cancer and bronchoscopic ablative modalities. We searched PubMed with the following search terms: bronchoscopic/ablation techniques and lung neoplasms. We limited our search to the past 10 years (given the more recent focus on cancer immunology), English language and human based publications. Articles that focused on diagnostic bronchoscopic techniques were excluded or limited.

Understanding immunotherapy in lung cancer

Driver mutations (Table 1) occur in cancer cells within genes responsible for cell growth and survival. They are found in about 64% of patients with NSCLC (26). Identification of some of these mutations, most notably EGFR mutation, ALK-1 translocation and ROS-1 translocation has led to a paradigm shift in cancer therapy since the early 2000s. Along with extent of disease, squamous vs. non-squamous history and programmed death ligand (PD-L1) expression, driver mutations heavily influence the choice of therapy in advanced NSCLC. Molecular testing for these driver mutations is mostly done by polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), next-generation sequencing (NGS) and immunohistochemical (IHC) analysis. Another increasingly popular molecular diagnostic tool is liquid biopsy (which is beyond the scope of this paper). The Lung Cancer Mutation Consortium published data in 2014 that showed a survival benefit (median survival 3.5 vs. 2.4 years) in patients receiving driver mutation targeted therapy with tyrosine kinase inhibitors (TKIs) as opposed to patients who did not (27).

Mutations in EGFR

Therapies against EGFR mutations were the first step towards molecular directed NSCLC therapy. These mutations are mostly seen in exon 19 (deletion) or exon 21 (L858R point mutation) and are detected either in solid tumor biopsies or in liquid biopsies using PCR. They are observed in about 15% of NSCLC. They are found in 10–20% of Caucasian patients but in about 48% of Asian patients with lung cancer (5). Higher incidence of this mutation is also seen with an adenocarcinoma histology, in never smokers, younger patients and in females (6,7). In advanced NSCLC, the presence of EGFR mutation confers a more favorable prognosis. Compared to first line chemotherapy, EGFR TKIs significantly prolonged progression free survival (4.6 to 6.9 months) (8). These include first generation EGFR TKIs (erlotinib, gefitinib), second generation EGFR TKIs (afatinib) and third generation EGFR TKIs (osimertinib).

Translocations in ALK

This translocation is seen in 1–7% of NSCLC (9,10). It involves an inversion in chromosome 2 that juxtaposes the 5’ end of the echinoderm microtubule-associated protein-like
<table>
<thead>
<tr>
<th>Mutations with FDA approved therapies</th>
<th>Features</th>
<th>Epidemiology</th>
<th>Detection</th>
<th>Genotype directed therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutations with FDA approved therapies</td>
<td>· Seen in exon 19 or exon 21; · Confers a more favorable prognosis</td>
<td>· 15% of NSCLC; · 10–20% of Caucasian patients; · 48% of Asian patients; · More common in adenocarcinoma histology, never smokers, younger patients and in females</td>
<td>· Solid and liquid biopsies; · PCR</td>
<td>· First generation-erlotinib, gefitinib; · Second generation-afatinib; · Third generation-osimertinib</td>
</tr>
<tr>
<td>ALK translocation (9-13)</td>
<td>· Translocation resulting in a fusion oncogene EML4-ALK</td>
<td>· 1–7% of NSCLC; · same frequency in Asian and Western populations; · More common in never smokers, younger patients and in adenocarcinoma with signet ring or acinar histology</td>
<td>· FISH; · IHC; · NGS panels</td>
<td>· First generation: crizotinib, alectinib (preferred), ceritinib; · Second generation: brigatinib, lorlatinib, ensartinib</td>
</tr>
<tr>
<td>ROS1 translocation (14-16)</td>
<td>· Translocation between ROS1 and CD74</td>
<td>· 1–2% of NSCLC; · More common in adenocarcinoma histology, younger patients and never smokers</td>
<td>· FISH; · NGS panels</td>
<td>· First line: crizotinib; · Second line: ceritinib, cabozantinib</td>
</tr>
<tr>
<td>BRAF mutation (17-20)</td>
<td>· Mutation can occur either at the V600 position of exon 15 or outside this domain</td>
<td>· 1–3% of NSCLC; · More common in smokers</td>
<td>· PCR; · NGS panels</td>
<td>· Usually combined with MEK inhibitor; · Dabrafenib plus Trametinib</td>
</tr>
<tr>
<td>Mutations with off label therapies</td>
<td>Mutations typically involve in frame insertions but can occur as a point mutation in exon 20 as well</td>
<td>· 1–3% of NSCLC; · More common in adenocarcinomas, never smokers and in women</td>
<td>· PCR; · NGS panels</td>
<td>· Afatinib or trastuzumab in combination with vinorelbine/docetaxel or ado-trastuzumab emtansine</td>
</tr>
<tr>
<td>HER2 mutations (21)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MET abnormalities (22,23)</td>
<td>· Exon 14 skipping mutations: 3% of adenocarcinomas and up to 20% of pulmonary sarcomatoid carcinomas; · MET gene amplifications: 2–4% of NSCLC; · MET-EGFR comutations: 5–20% of EGFR inhibitor treatment resistance NSCLC</td>
<td>· FISH; · NGS panels</td>
<td>· Crizotinib, cabozantinib</td>
<td></td>
</tr>
<tr>
<td>RET translocations (24,25)</td>
<td>· Recurrent translocations RET and various fusion partners</td>
<td>· 1–2% of adenocarcinomas; · More common in younger patients and never smokers</td>
<td>· FISH; · NGS panel</td>
<td>· Cabozantinib, vandetanib, alectinib</td>
</tr>
</tbody>
</table>

FDA, Food and Drug Administration; EGFR, epidermal growth factor; ALK, anaplastic lymphoma kinase; ROS1, rat osteosarcoma; HER2, human epidermal growth factor receptor 2; MET, mesenchymal epithelial transition; RET, rearranged during transfection; NSCLC, non-small cell lung cancer; PCR, polymerase chain reaction; FISH, fluorescence in situ hybridization; NGS, next-generation sequencing; IHC, immunohistochemical.
4 (EML4) gene with the 3’ end of the ALK gene, resulting in the fusion oncogene EML4-ALK. Higher incidence of this translocation is seen in never smokers, younger patients and in adenocarcinoma with signet ring or acinar histology (11). This gene arrangement is mutually exclusive with EGFR and KRAS mutations (11) and is seen in the same frequency in Asian and Western populations (12). ALK translocations can be identified by FISH, IHC or NGS panels. Advanced NSCLCs with ALK fusion oncogene are highly sensitive to ALK TKIs. Crizotinib, a TKI originally developed as a c-MET kinase inhibitor, has shown significant activity in patients with ALK and ROS1 translocation. Compared to first line chemotherapy, Crizotinib significantly prolonged progression free survival (10.9 vs. 7.0 months) (13). Other ALK TKIs include alectinib (now preferred first line) and ceritinib. Second generation ALK TKIs in clinical development, mostly for crizotinib refractory NSCLC, include brigatinib, lorlatinib and ensartinib.

Translocations in ROS1

ROS1 translocation, typically between ROS1 and CD74 (14), is seen in about 1–2% of NSCLC (15). Higher incidence of this translocation is seen with adenocarcinoma histology, younger patients and never smokers. This translocation can be identified by FISH or by some NGS panels. ROS1 TK is highly sensitive to crizotinib (response rate of 72%; median progression free survival 19.2 months) (16). Second line agents being studied include ceritinib and caboazitinib.

Mutations in BRAF

BRAF is a downstream signaling mediator of KRAS that activates the mitogen-activated protein kinase (MAPK) pathway. This mutation is seen in about 1–3% of NSCLC and is more common in smokers (17). It is usually detected by PCR or by NGS methods. This mutation can occur either at the V600 position of exon 15 (as in melanoma) or outside this domain. Never or light smokers with this mutation tend to have it more often in the V600 position than the non-V600 position (18). The prognosis is better with the V600 mutation than the non-V600 mutation. Current Food and Drug Administration (FDA) approved therapy for this mutation is usually combination with a MEK inhibitor. In advanced previously treated NSCLC, Dabrafenib plus trametinib was associated with a 63% response and 79% disease control rate with a median progression free survival rate of 9.7 (19) to 10.9 months (20).

Other genotypes with off-label therapies

HER2 mutations can be detected by PCR or NGS in 1–3% of NSCLC (21). These mutations typically involve in frame insertions in exon 20 but can occur as a point mutation in exon 20 as well. They are more common in adenocarcinomas, never smokers and in women. For advanced previously treated NSCLC with HER2 exon insertion, afatinib or trastuzumab in combination with vinorelbine/docetaxel or ado-trastuzumab emtansine can be used.

MET abnormalities include exon 14 skipping mutations (3% of adenocarcinomas and up to 20% of pulmonary sarcomatoid carcinomas), MET gene amplifications (2–4% of NSCLC) and MET-EGFR comutations (5–20% of EGFR inhibitor treatment resistance NSCLC) (22,23). They are detected by NGS panels or by FISH. For advanced previously treated NSCLC, MET inhibitors such as crizotinib and caboazitinib can be used.

Recurrent translocations RET and various fusion partners, detected by FISH and NGS, have been seen in 1–2% of adenocarcinomas and typically occur in younger patients and never smokers (24,25). For advanced previously treated NSCLC, caboazitinib, vandetanib and alectinib can be used.

Other genotypes with ongoing clinical trials include RAS mutation (MEK inhibition with trametinib and selumetinib) and PIK3CA, AKT1, PTEN alterations.

Role of ablative bronchoscopic procedures in lung cancer

Interventional bronchoscopy (Table 2) has an ever-increasing role in the management of advanced lung cancers. The AQuIRE Bronchoscopy Registry looked at 1,115 procedures on 947 patients (66). The technical success for airway reopening was ~93% with clinically significant relief in dyspnea and improvement in quality of life. Patients with higher dyspnea and lower functional status benefited the most. While the complication rates varied heavily between centers (based on sedation type, use of rigid bronchoscope, type of ventilation and use of stents), the overall rate was still low at about 3.9% (67). Multiple factors have influenced the choice of modality.
used to manage central airway tumors. These typically involve patient/treatment factors, such as inability to tolerate surgery or “older” generation chemotherapeutic agents. Tumor factors considered usually refer to locations, size and severity of obstruction. The obvious lack of genotype consideration in procedure selection does warrant discussion given advancements made in this area.

**Rigid bronchoscopy with mechanical debulking**

The choice between initial flexible vs. rigid bronchoscopy for tumor assessment and management remains controversial. While the complication rates are lower and less serious with flexible bronchoscopy (<1% to 6.8% vs. ~20%) (28-32), rigid bronchoscopy allows for a more secure airway and possibly safer extended periods for ablative procedures. Older literature supports mechanical debulking with the beveled end alone to “core out” the tumor (airway improvement in 90% of patients with need for repeat bronchoscopy in <5% of patients) (32). In the modern era rigid bronchoscopy is more commonly combined with another ablative or “thermal” modality. As with other procedures, operator experience plays an important role in limiting complications (especially bleeding and airway perforation) while increasing success.

**Laser**

‘Light amplification by stimulated emission of radiation’ uses light energy to ablate (by coagulation or direct destruction) tumors and/or achieve hemostasis by vessel photocoagulation. Laser is mainly indicated for central intraluminal lesions with short length involvement (<4 cm) and minimal submucosal infiltration (33,34). Laser is often
and successfully used with rigid bronchoscopy with good restoration of bronchial diameter especially in proximal tumors (trachea and main bronchus) (35). Use of laser in studies has shown improved symptom scores, quality of life, gas exchange and lung function (36-38). Rates of complication, such as severe hemoptysis, and mortality rate associated directly with laser are low (<1%) (38). The risk of ignition or airway fire can be prevented by lowering the FiO₂ to <40%. Fatal complications described with laser such as gas embolisms, vascular fistula and mediastinitis (39,40) are very rare. A major limitation with this modality is the cost of the generator and the single-use laser probes.

**Thermo-coagulation/electrocautery & APC**

Electrocautery involves use of high-frequency electric current to deliver thermal energy from the tip of a probe. It can be set for coagulation (at low-power setting, soft-coagulation) or vaporization/carbonization (at high-power settings, forced-coagulation) (34). This energy can be delivered by different applicators such as a monopolar probe, bipolar probe, or electric snare, loop, or knife. Electrocautery, unlike laser, has a less deep effect and is ideal for superficial coagulation. While the rate of symptom palliation and lung function improvement observed with electrocautery is similar to laser (41,42,68), the costs of electrocautery are substantially cheaper. Major complications with electrocautery are rare, more so with the soft coagulation mode (43). If applied circumferentially thermocoagulation can cause scarring stenosis (68).

APC is a non-contact form of electrocautery that uses ionized argon as the electrical current. It overcomes 2 limitations noted with electrocautery (I) the ability to access most apical segments (II) improved efficacy in cases of electric current induced bleeding. Argon has the ability to travel upstream in the bloodstream and hence result in hemostasis at the origin of bleeding (41), making it particularly effective in controlling bleeding. As with electrocautery, APC is ideal for superficial coagulation and is mainly indicated for extensive/hemorrhagic tumors prior to mechanical debulking.

In conclusion, both electrocautery and APC are effective low-cost methods of thermocoagulation. They appear to be as effective if not superior to laser in most situations except in bulky exophytic tumors where a deeper coagulation is required.

**Cryotherapy**

Cryotherapy uses probes or a spray to deliver cryogenic gases (N₂O, N₂, CO₂) at very low temperatures (~196°C). Cryotherapy has an immediate effect (dehydration and cellular crystallization) and a delayed effect (apoptosis and ischemia) making it an effective short and longer-term modality (3,44). The treatment site is extensive, making cryotherapy ideal for very hemorrhagic tumors where the exact bleeding site is not known. As with other therapies, cryotherapy has been shown to improve airway diameter, performance status and lung function (45,46). Procedure related mortality is low (~1.2%) with total complication rates <10% (47). As with thermocoagulation, cryotherapy is very cost effective but without the risk of scarring stenosis and with the benefit of an added delayed effect. Finally, cryotherapy can be safely delivered around stents without damaging the prosthesis (4).

**EBT**

EBT involves deploying radioactive isotopes (iridium 192) in a highly localized manner through a specialized catheter in order to preserve neighboring lung tissue (33). It is used as a sole intervention or in conjunction with external beam radiation either for palliation or curative treatment in selected cases of small tumors (<3 cm) (48). Despite its potential role in radio-occult lesions and in patients who are poor surgical candidates (contralateral pneumonectomy or respiratory insufficiency), use of EBT is limited by its poor safety profile. Major complications can be seen in 13–20% of the cases (49). While massive hemoptysis can be seen in up to 7% of the cases (49), radiation bronchitis with subsequent necrosis and abscess formation can occur in up to 35% of patients (50,51).

**PDT**

PDT involves tumor destruction by use of a photosensitizing agent (usually a hematoporphyrin derivative) with a light source (630 nm). This results in a phototoxic reaction and cell death (3,33,52). PDT typically results in marked, yet delayed, symptom improvement and is not suitable for acute critical proximal obstruction. Repeat bronchoscopy is performed 1–2 days later for removal of necrotic tissue and then 5–7 days later for a second illumination (52,53). PDT is particularly effective in controlling hemoptysis and relieving dyspnea. Lung function improvement is achieved.
in a majority of the cases (53). A phototoxic reaction is noted in 5–28% of patients and fatal hemoptysis is seen in ~18% of cases (52). Periprocedural mortalities are usually not treatment related (54).

**ITC and TBNI**

While the previously mentioned modalities are mainly directed at acutely managing tumors, ITC and TBNI therapy maybe the first step towards a direct bronchoscopic tumor intervention. Initially, advantages of ITC/TBNI considered included more precision drug delivery, higher tumor drug concentration and less or no systemic toxicity (55). However, emerging evidence suggests that this modality has systemic benefits (and toxicity) and may be used as an adjunct with other interventions such as low dose chemotherapy (56). Needle-catheters used for drug delivery are the same as those used for therapeutic aspiration. In these procedures, chemotherapeutic agents can be injected directly into luminal tumors or into thoracic lymph nodes with the assistance of endobronchial ultrasonography (EBUS). While ITC has been well studied for delivery of chemotherapeutic agents (such as Cisplatin, 5-Fluorouracil, Bleomycin and Carboplatin) (57,58) it has also been studied for delivery of therapeutic genes via viral vector (59-61).

In an early clinical study (1986–1992) involving 93 patients with inoperable cancer, sequential injection of 5-Fluorouracil, Mitomycin-C, Methotrexate, Bleomycin and Mitoxantrone showed improved airway lumen in 87% of cases with >50% obstruction (57). In another study done in 2000, intratumoral Carboplatin combined with systemic chemotherapeutic resulted in a better response rate (90% vs. 55%), tumor size and dyspnea relief when compared to systemic chemotherapy alone in patients with advanced bronchogenic carcinoma (58). Endobronchial ultrasound guided needle lymph node drug delivery was demonstrated successfully in a study involving 5 patients with EGFR negative advanced bronchogenic cancer who were unfit (performance status 2/PS2) for surgery, radiation and chemotherapy (56). In this proof of concept study, a TBNI protocol using Cisplatin combined with low dose systemic chemotherapy (70% of standard) was well tolerated by these sick patients with good survival. Since then EBUS-TBNI for drug delivery has been used successfully in patients with severe COPD who had a response enough to tolerate systemic chemotherapy later (62), in patients with local (63) as well as isolated mediastinal/hilar recurrence (64) and also in patients with aspergilloma (65). Studies (BROADWAY, clinicaltrials.gov, NCT02066103) using a new micro-infusion device, Blowfish™ (Mercator MedSystems, Emeryville, CA, USA) are ongoing. Early scientific abstracts suggest that paclitaxel can be delivered safely after rigid bronchoscopy using this specialized catheter in patients with malignant CAO, obviating the need for airway stenting.

While there are no major side effects reported from ITC, systemic effects are noted. In one study patients were reported to have neutropenia (1,800 leucocytes per μL) after the first intratumoral cisplatin administration (56). Local airway effects appear minimal. Local blanching and decreased tumor bleeding are interesting observations (55,56) that would suggest acute interruption of perfusion or a “shock reaction” of the tumor. Larger experience is needed with this modality for identify other complications.

**Other considerations about tumor responsiveness and immunotherapy**

Evolution or change in genotype has been reported before and is a cause of concern for genotype directed therapies (69). The postulations for EGFR mutation change pre and post therapy include the influence of chemotherapy on driver mutations and intratumoral heterogeneity causing a mis-representation of mutational status during initial sampling (70). Smaller nodules appear to have less intratumoral heterogeneity (71) which could explain better long term survival even in the same T-stage descriptor (72). These findings may also be an explanation for the emergence of TKI resistance and treatment failure.

The immune modulatory effects of ablative procedures in cancer is intriguing. It has been well documented with radiofrequency ablation (RFA), cryoablation, microwave ablation therapy, high-intensity focused ultrasound and laser thermotherapy (73). Cryotherapy, for example, is known to increase levels of soluble interleukin-2 receptor, ILD and lymphocyte transformation rate (74). It could also provoke a direct anti-tumor immunity by activating dendritic cells (DCs). Similarly, PDT is known to enhance anti-tumor immunity (75). PDT is known to activate cell mediated (CD8+ T cell), and to a lesser extent humoral, anti-tumor immunity (76,77). In animal models, PDT ablated mice were able to resist a subsequent tumor challenge (76). In the clinical setting, PDT treated head and neck tumors were noted to have increased immune cell infiltration in distant untreated sites (78) and combing PDT with radical lung sparing pleurectomy for mesothelioma resulted in a less
aggressive form of recurrence (79); suggesting enhanced tumor immunity. Interestingly, PDT is synergistic with checkpoint inhibitors, such as anti-PD-1/ PD-L1, and results in prolonged anti-tumor immune response (80,81). Similar synergism, where PDT is combined with immunomodulating agents, may also been seen the treatment of other cancers such as vulvar intraepithelial neoplasia(82) and actinic keratosis/ Bowens disease (83) as MHC-I recognition with subsequent CD8⁺ T-cell activation appears to be a key factor for tumor responsiveness. The future of bronchoscopic modalities may also include combinations local tumor RFA with intravenous Paclitaxel and Doxorubicin. Murine model studies have already demonstrated augmented RFA tumor coagulation and end-point survival with such multi-modality approaches (84). This insight could theoretically translate a multi-step modality. For example, post rigid bronchoscopy debulking local Paclitaxel delivery with the Blowfish™ (Mercator MedSystems, Emeryville, CA) device could be followed by RFA treatment.

Finally, a professional antigen presenting cell that plays a key role in tumor immunity are dendritic cells (DCs). Immunogenic cell death is characterized by release of damage-associated molecular patterns (DAMPs) (85). DAMPs play a key role in the maturation of DCs. DCs in turn capture, process and present tumor antigens to the appropriate Th1 cells while ultimately leads to the activation of cytotoxic CD8⁺ T lymphocytes (86) and hence tumor immunity. Given the tissue damage associated with bronchoscopic ablative modalities, it is quite possible that these procedure result in release in DAMPs, activations and even attraction of DCs to this area and hence development of tumor immunity (87). For example, PDT is known to result the maturation and activation of DCs (88,89). Studies to validate this phenomenon with other modalities are sorely needed. Cisplatin is a systemic immunogenic cell death inducer and in this way a DAMP. Future studies could be centered on its DC maturing effect (hence cancer immunity boosting) via ITC with a staged systemic chemotherapy regimen.

The bronchoscopist in the era of genotype directed lung cancer management

Referral patterns are shifting, and a change in diagnostic algorithms frequently makes a bronchoscopist the first provider to encounter the patient and the tumor. Reported EBUS-TBNA and EUS-FNA adequacy rates (ranging from 77–98%) (90,91) almost completely obviates the need for more invasive surgical tumor sampling. In fact, EBUS-TBNA has one of the lowest insufficiency rates (4%) for EGFR and KRAS mutation analysis; compared to CT guided needle aspiration (7.5%) and ultrasound guided superficial fine needle aspiration (10%) (91). Given that ~25% of patients with enlarging lymph nodes following curative NSCLC surgery have a second primary lung cancer (92), a bronchoscopist also plays a role in the long term follow-up/restaging of these patients. This is also important given the emergence of acquired resistance to the newer TKIs.

The cause of acquired resistance is not fully understood. It is proposed that resistance to EGFR TKIs could be the result of a secondary mutation in EGFR (most commonly substitution of methionine for threonine at position 790 i.e., T790M) (93,94) or the amplification of the MET oncogene (which can occur with or without the T790M mutation) (24). Regardless of the mechanism, a bronchoscopist may be required to resample the tumor at this point when the patients are frequently very sick. Insight into driver mutations while deciding on the optimal therapeutic modality is analogous, in some ways, to knowledge on TNM staging while EBUS-TBNA lymph node staging.

Another evolving concept in advanced NSCLC is the abscopal response noted with combination of radiation and immunotherapy (95). This rare phenomenon, wherein distant lesions regress after radiotherapy to a targeted site has been, has been described for many years now (96). In one study, 25% of melanoma patients showed regression of non-irradiated lesions when immunotherapy was continued after radiation to the tumor site after it had failed immunotherapy alone (anti-PD-1 monotherapy) (97). It was first reported in 2013 in a patient with treatment refractory lung cancer treated with radiotherapy and Ipilimumab (anti-CTL4-monoclonal antibody) (95). The concept of “boosting” immune responses to treat remote lesions opens another avenue for the bronchoscopist. It would be intriguing to explore whether such a response is also noted (or exaggerated) based on the ablative modality used (for example: EBT vs. PDT vs. APC).

There is a plethora of questions that remain unanswered. What is the effect of various bronchoscopic ablative procedures on tissue sampling for advanced previously treated NSCLC? Does the procedure itself have any effect of driver mutation either in vivo or ex vitro? Should driver mutations influence our choice of modality? Is there an abscopal response noted with different modalities as noted
with radiotherapy combined with immunotherapy?

**Conclusion/future direction**

Ground breaking advances in our understanding of driver mutations of lung cancer and in the technology available for bronchoscopic ablation have completely changed the landscape of advanced lung cancer management. As the two fields progress in parallel, we must ask ourselves if they should be bought together in the name of precision medicine. We must also wonder if genotypes of cancer produce specific endotypes and whether these endotypes respond differently to each bronchoscopic modality.

**Acknowledgements**

None.

**Footnote**

Conflicts of Interest: MR Bowling is a Consultant for Medtronic, Biodesix and Veracyte. W Hohenforst-Schmidt is a Consultant for Medtronic and Philips. Other authors have no conflicts of interest to declare.

**References**


34. Speiser BL, Spratling L. Remote afterloading


